Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
2678 articles with Eli Lilly and Company
-
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19
11/9/2020
The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg.
-
Clinical Catch-Up: November 2-6
11/9/2020
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look. -
Aarti Shah to Retire as Lilly Chief Information and Digital Officer
11/5/2020
Eli Lilly and Company announced that Aarti Shah, Ph.D., senior vice president and chief information and digital officer, will retire in the first half of 2021 after 27 years of service with the company.
-
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
10/31/2020
Baricitinib was recently approved by the European Commission, representing the first global approval for the medicine in atopic dermatitis
-
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata
10/30/2020
Data support baricitinib's ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA)
-
New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis
10/29/2020
Eli Lilly and Company (NYSE: LLY) announced today it will share new Taltz® (ixekizumab) data from multiple long-term and post-hoc analyses that indicate sustained efficacy in patients with psoriasis and psoriatic arthritis.
-
Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19
10/28/2020
Eli Lilly and Company announced an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab 700 mg, an investigational neutralizing antibody, for $375 million.
-
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine
10/28/2020
The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) – a neutralizing antibody – in the COVID-19 outpatient setting. This study focused on ambulatory COVID-19 patients being treat
-
Lilly Reports Third-Quarter Financial Results, Updates Guidance
10/27/2020
Revenue in the third quarter of 2020 increased 5 percent driven by volume growth of 9 percent, while on a year-to-date basis revenue increased 6 percent driven by volume growth of 12 percent.
-
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
-
Lilly Declares Fourth-Quarter 2020 Dividend
10/19/2020
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock.
-
UCB Snags Eli Lilly U.K. Research Site, Plans to Invest £1 Billion Over Five Years for R&D
10/16/2020
UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey. -
Lilly Announces Agreement to Acquire Disarm Therapeutics
10/15/2020
Acquisition expands Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's promising preclinical SARM1 programs for axonal degeneration [15-October-2020] INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-he
-
Several biopharmaceutical companies have made headway as of late in the race to develop a vaccine for COVID-19, which is responsible for the current global pandemic.
-
Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.
-
Glitches in the COVID-19 Race: Less than 24 Hours After J&J Pauses Vaccine Trial, Eli Lilly Pause...
10/13/2020
Eli Lilly announced that it is pausing its clinical trial of a combination antibody against COVID-19 over safety concerns. Typically, this would be because a patient or volunteer showed a serious side effect or became sick, but the company did not clarify what the reason for the pause is. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
-
Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial
10/12/2020
Results from the 52-week study showed continued symptom improvement and reduction of intestinal mucosal inflammation in patients with moderately to severely active Crohn's disease
-
Innovent and Lilly expect Halpryza to be a high quality and slightly more affordable rituximab injection for a market experiencing serious needs.